2022 ALS Scholars in Therapeutics recipients announced

FightMND, partnering with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and ALS Finding a Cure®, have selected three successful researchers for the global two-year ALS Scholars in Therapeutics program.

The ALS Scholars in Therapeutics program provides funding to young investigators, empowering them to gain training and experience in developing new treatments for people living with Amyotrophic Lateral Sclerosis (ALS).

ALS is the most common form of Motor Neurone Disease (MND), accounting for roughly 60-70% of all MND cases.

From an outstanding pool of applicants, this year’s successful ALS Scholars are:

  • Dylan Galloway, PhD of the Washington University School of Medicine,
  • Jacob Mann, PhD of Northwestern University Feinberg School of Medicine, and
  • Roberta Piovesana, PhD of the University of Montreal.

All scholars will be part of the broader Healey & AMG Center, ALS Finding a Cure® and FightMND’s global community, and importantly, they will engage directly with people living with MND.

For more information about their specific areas of research, please visit this website.

FightMND is one of the largest independent funders of MND research in the world. Since 2014, FightMND has invested more than $55.9M into vital and urgent MND research.

The pillars that underpin FightMND’s investment to find a cure for MND include funding world class research, international collaboration, strengthening the research workforce and making targeted investments that facilitate MND research globally.

Every researcher we add to the fight means that effective treatments will be found sooner. By engaging motivated and creative individuals with a passion for bringing treatments to people living with MND, we are helping to expand the community of experts and expedite therapy development.